Analysis

J&J's Litigation Bravado In Sharp Relief After Epic Opioid Trial

Law360 (September 20, 2019, 7:23 PM EDT) -- Johnson & Johnson's decision this year to risk a $17 billion penalty in the nation's first opioid-crisis trial added one of the most dramatic chapters yet to the company's increasingly remarkable willingness to spurn settlements and litigate financially perilous cases all the way.

People walk along a corridor at Johnson & Johnson's headquarters in New Brunswick, New Jersey. The health care giant has shown a penchant for litigating cases instead of settling them. (AP) The health care titan's litigation bravado was practically undeniable when it charged all alone into a summerlong trial on the home turf of a state hit hard by...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS